---

Test: CMD Pharmacology

Topic: Non-Clinical Pharmacology & Analytical Biochemical Assay

---

Q1. (a) Discuss In Silico, In Vitro & In Vivo Studies with Examples [5 Marks]

In Silico Studies

• Molecular docking (predicting drug-receptor interactions)
• Quantitative Structure-Activity Relationship (QSAR) modeling
• Pharmacokinetic modeling (ADME prediction)
• Virtual screening of chemical libraries
• Molecular dynamics simulation

• Predicting whether a new compound will inhibit COX-2 using molecular docking
• Predicting blood-brain barrier penetration using lipophilicity algorithms
• Screening millions of compounds against HIV protease in silico before synthesis
• ADMET prediction using software like Discovery Studio, AutoDock, Schrodinger

• Fast, inexpensive, no animal use
• Can screen huge compound libraries
• Predicts toxicity early (saving costs)

---

In Vitro Studies

• MTT assay for cytotoxicity on HeLa cells
• Ames test (Salmonella mutagenicity test) - genotoxicity testing
• Human liver microsome assay for CYP450 metabolism
• PAMPA assay for membrane permeability
• Protein binding studies using equilibrium dialysis

• Controlled conditions, reproducible
• No animal suffering
• Can study single variables
• Mechanistic insight

---

In Vivo Studies

• Acute, sub-acute, subchronic, and chronic toxicity studies
• Pharmacodynamic studies (e.g., hot plate test for analgesia)
• Pharmacokinetic studies (AUC, Cmax, t1/2)
• Teratogenicity and reproductive toxicity
• Efficacy studies in disease models

• Tail flick test / hot plate test in mice - analgesic activity
• Streptozotocin-induced diabetes in rats - antidiabetic activity
• Pentylenetetrazole (PTZ) model in mice - anticonvulsant activity
• Acetic acid-induced writhing test - anti-inflammatory activity
• LD50 determination using acute toxicity in rodents

• Reflects whole-body physiology
• Accounts for absorption, distribution, metabolism, excretion
• Required by regulatory agencies before human trials

---

Comparison Table

---

Q1. (b) Discuss First Dose Estimation in Humans [5 Marks]

Definition

Objectives

1. To establish a safe starting dose
2. To avoid serious adverse events in first-in-human trials
3. To satisfy regulatory requirements (ICH, FDA, EMA guidelines)

Methods of First Human Dose Estimation

1. NOAEL-Based Approach (Most Common)

• NOAEL = No Observed Adverse Effect Level - the highest dose in the most sensitive animal species that produces no adverse effect.
• Human equivalent dose (HED) is calculated:

• A safety factor of 10 is typically applied:

2. MABEL Approach (Minimum Anticipated Biological Effect Level)

• Used for high-risk biologics/monoclonal antibodies (e.g., after TGN1412 disaster in 2006)
• Based on the lowest dose producing any pharmacological effect in the most sensitive species
• More conservative than NOAEL-based approach

3. PAD (Pharmacologically Active Dose)

• Based on in vitro potency (e.g., IC50, EC50) and pharmacokinetic data
• Useful when NOAEL is not clearly defined

4. Microdosing (Phase 0 Studies)

• Sub-therapeutic dose of radiolabeled compound (1/100th of NOAEL or 100 micrograms max)
• Gives early PK data in humans without significant pharmacological effect

Regulatory Guidelines

• FDA Guidance: "Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers" (2005)
• ICH M3(R2): Non-clinical safety studies
• EMA Guideline on FIH clinical trials (2017)

Steps Summary

1. Conduct toxicology studies in at least 2 species (rodent + non-rodent)
2. Determine NOAEL from animal studies
3. Convert to HED using BSA correction
4. Apply safety factor (minimum 10-fold)
5. Cross-check with pharmacologically active dose
6. Select lowest value as MRSD

---

Q2. (a) Carcinogenicity Studies & Genotoxicity Studies [5 Marks]

Genotoxicity Studies

Standard Test Battery:

• Organism: Salmonella typhimurium and Escherichia coli strains
• Detects: Point mutations (base pair substitutions, frameshifts)
• With/without metabolic activation (S9 rat liver microsomal fraction)
• Result: Increased revertant colonies = mutagenic

• Cell line: Chinese hamster ovary (CHO) or human lymphocytes
• Detects: Clastogenic (chromosome breaks) or aneugenic (spindle damage) effects
• Micronuclei = fragments of chromosomes not incorporated into daughter nuclei

• Rodent bone marrow or peripheral blood erythrocytes
• Detects in vivo clastogenicity/aneugenicity
• Gold standard for regulatory genotoxicity assessment

• Detects: DNA strand breaks in individual cells
• Tail moment indicates DNA damage extent

• Detects point mutations and small deletions at the thymidine kinase (TK) locus

---

Carcinogenicity Studies

• Drug intended for use > 6 months
• Drug used intermittently for chronic conditions
• Drug is genotoxic positive

Study Design

Endpoints:

• Incidence of benign and malignant tumors
• Tumor type, organ, latency
• Body weight, survival
• Histopathology of all organs

Alternative Models for Carcinogenicity:

• Transgenic mouse models (p53+/- heterozygous knockout, rasH2 mice) - shorter duration (26 weeks)
• Newborn mouse assay for non-genotoxic carcinogens

Mechanism Types:

• Genotoxic carcinogens: Direct DNA damage (e.g., aflatoxin, cyclophosphamide) - no threshold
• Non-genotoxic carcinogens: Epigenetic mechanisms, receptor-mediated (e.g., phenobarbital, hormones) - threshold exists

---

Q2. (b) Transgenic Animals in Experimental Research [5 Marks]

Definition

Methods of Creating Transgenic Animals

1. Microinjection - Foreign DNA injected directly into pronucleus of fertilized egg
2. Retroviral vectors - Viral vectors used to insert genes into embryonic cells
3. Embryonic stem (ES) cell technology - Gene targeting in ES cells, then chimera creation
4. CRISPR-Cas9 - Modern precise gene editing technology
5. Somatic cell nuclear transfer (cloning)

Types of Genetic Modifications

Applications in Experimental Research

1. Disease Models

• Alzheimer's disease: APP/PS1 transgenic mice (amyloid plaques)
• Diabetes: NOD (Non-Obese Diabetic) mice, db/db leptin receptor knockout mice
• Cancer: p53 knockout mice, BRCA1/2 KO mice
• Cardiovascular disease: ApoE knockout mice (atherosclerosis model)
• Cystic fibrosis: CFTR knockout mice

2. Drug Target Validation

• Gene knockout identifies if a target is essential for disease
• Humanized receptors allow testing of drugs designed for human targets

3. Pharmacogenomics

• CYP knockout mice to study drug metabolism
• P-glycoprotein knockout mice for drug transport studies

4. Production of Therapeutic Proteins (Pharming)

• Transgenic goats/cows produce human proteins in milk
• e.g., ATryn (antithrombin III) from transgenic goats

5. Safety/Toxicology Testing

• rasH2 and p53+/- mice for short-term carcinogenicity screening (26 weeks vs. 2 years)
• Reporter gene assays for genotoxicity

6. Vaccine Development

• Humanized mice with human immune system for vaccine testing

Advantages

• Provide targeted, precise disease models
• Reduce number of animals needed
• Allow mechanistic understanding of disease
• Predictive of human disease when humanized

Disadvantages

• Expensive and time-consuming to create
• Compensatory mechanisms may mask phenotype
• Species differences remain
• Ethical concerns

Regulatory Aspects

• Animals covered under CPCSEA (India), IACUC (USA), AAALAC guidelines
• Contained facilities required for genetically modified organisms

---

Q3. (a) Short Note on OECD [5 Marks]

Introduction

OECD in the Context of Pharmacology and Toxicology

OECD Test Guidelines - Major Categories

Important OECD TGs in Toxicology

OECD Principles of Good Laboratory Practice (GLP)

• Quality and integrity of non-clinical safety data
• Mutual acceptance of data (MAD) among member countries
• Study director accountability
• Standard operating procedures (SOPs)
• Archive and audit trail requirements

OECD's Role in Reducing Animal Testing

• IATA (Integrated Approaches to Testing and Assessment)
• Development and validation of in vitro and in silico alternative methods
• OECD QSAR Toolbox for chemical hazard prediction

Significance

---

Q3. (b) Principles of Handling and Care of Lab Animals with Special Reference to CPCSEA Guidelines [5 Marks]

Introduction

CPCSEA - Committee for the Purpose of Control and Supervision of Experiments on Animals

• Established under: Prevention of Cruelty to Animals (PCA) Act, 1960
• Ministry: Ministry of Fisheries, Animal Husbandry and Dairying, Government of India
• Role: Registers and monitors animal facilities; approves experiments; enforces IAEC compliance

CPCSEA Guidelines - Key Principles

1. The 3Rs Principle (Russell & Burch, 1959)

• Replacement - Use alternatives (in vitro, in silico) wherever possible
• Reduction - Use minimum number of animals needed (statistical justification)
• Refinement - Minimize pain, distress, and improve procedures

2. Institutional Animal Ethics Committee (IAEC)

• Every institute must constitute an IAEC (minimum 7 members)
• Members: Biological scientist, medical professional, veterinarian, CPCSEA nominee, social scientist, nominee of State AWB, and a prominent person
• All experiments must be approved by IAEC before commencement

3. Housing Requirements

• Clean, well-ventilated animal house
• Temperature: 22 ± 3°C
• Humidity: 30-70%
• 12 hour light: 12 hour dark cycle
• Adequate cage size per species (standardized)
• Proper bedding material (sterile corn cob, wood shavings)

4. Feeding and Water

• Adequate, nutritious, uncontaminated food
• Autoclaved/irradiated diet for clean/SPF animals
• Clean water, changed regularly
• No cross-contamination between species

5. Handling Principles

• Minimal stress during handling
• Trained personnel only to handle animals
• Use appropriate restraining devices
• Avoid abrupt, rough handling
• Acclimatization period (minimum 5-7 days) before experiments

6. Health Monitoring

• Regular health checks by veterinarian
• Sentinel animal programs for SPF colonies
• Quarantine of new animals (minimum 2 weeks)
• Regular microbiological and parasitological monitoring

7. Record Keeping

• Complete records of animals used, source, health status
• Detailed protocol documentation
• IAEC approval records maintained

8. Training of Personnel

• All persons working with animals must be trained and certified
• Aware of species-specific behavior, anesthesia, analgesia, euthanasia

9. Anesthesia and Analgesia

• Appropriate anesthesia must be used for painful procedures
• Post-operative analgesia is mandatory
• Monitoring during recovery

10. Euthanasia

• Performed humanely using methods approved by CPCSEA/AVMA
• Done at end of experiment or if animal shows undue suffering

Recognized Animal Species (Schedule)

---

Q4. (a) Discuss Validation of Animal Models [5 Marks]

Definition

Why Validation is Needed

• To ensure scientific credibility of the model
• To confirm that pharmacological effects in animals translate to humans
• Required by regulatory authorities (OECD, FDA, ICH)
• To justify use of animals on ethical grounds

Criteria for Validation of Animal Models

1. Face Validity (Phenomenological Validity)

• The animal model shows behavioral/physiological features that resemble the human disease
• Example: Streptozotocin rats show hyperglycemia, polydipsia, polyuria - similar to diabetes
• It is the most basic level - superficial similarity to the disease

2. Construct Validity (Etiological Validity)

• The model is based on the same underlying biological mechanism (etiology/pathophysiology) as the human condition
• Example: 6-OHDA lesion of dopaminergic neurons as Parkinson's model - same mechanism (dopamine depletion) as human PD
• Strongest form of validity

3. Predictive Validity

• The model correctly predicts the effectiveness of treatments known to work in humans
• Example: Forced swim test in rats - antidepressants that work in humans (imipramine, fluoxetine) also reduce immobility in this test
• Most relevant for drug screening

4. Convergent Validity

• Multiple independent animal models give similar results for the same drug/treatment

5. Discriminant Validity

• Drugs that do NOT work in humans should NOT show activity in the model
• Prevents false positives in drug screening

Additional Validation Criteria

Steps in Validation of an Animal Model

1. Literature review - evidence from prior studies
2. Characterize the model - define key endpoints
3. Test positive and negative controls
4. Compare with human pathology data
5. Check inter-laboratory reproducibility
6. Regulatory submission and acceptance (OECD, ECVAM validation)

Examples of Validated Animal Models

---

Q4. (b) Euthanasia in Animals in Experimental Studies [5 Marks]

Definition

When Euthanasia is Required

• End of the experimental period
• Animals experiencing severe, unrelievable pain or distress
• Humane endpoints reached (defined criteria for early termination)
• Animals developing unexpected illness
• Surplus animals in a colony

Criteria for Acceptable Euthanasia (AVMA/CPCSEA)

1. Must cause minimal distress, pain, and anxiety
2. Must result in rapid loss of consciousness followed by cardiac/respiratory arrest
3. Must be reliable and reproducible
4. Must be appropriate for age, species, and size
5. Must be safe for the operator
6. Must be compatible with experimental objectives

Methods of Euthanasia

A. Physical Methods

B. Chemical Methods

C. Inhalant Agents

• CO2 gas chamber (rodents) - fill at 30-70% of chamber volume per minute
• Halothane/isoflurane overdose in induction chamber

Unacceptable Methods

• Drowning
• Air embolism (in conscious animals)
• Chloroform (uncontrolled, toxic to personnel)
• Freezing without prior anesthesia
• Strychnine

Humane Endpoints

• Pre-defined criteria that trigger euthanasia during a study:

  • 20% weight loss

  • Loss of righting reflex
  • Signs of severe infection/organ failure
  • Tumor size >10% body weight
  • Inability to reach food/water

Post-Euthanasia Confirmation

• Absence of heartbeat (auscultation)
• Absence of respiration
• Loss of eye reflexes
• Rigor mortis (after time)

---

Q5. (a) High Performance Liquid Chromatography (HPLC) [5 Marks]

Introduction

Principle

Instrumentation (Key Components)

1. Mobile phase reservoir - Contains the solvent system (eluent)
2. High-pressure pump - Delivers mobile phase at constant flow rate (1-2 mL/min) under high pressure (up to 400 bar)
3. Injector - Introduces sample into the mobile phase stream (manual syringe or autosampler)
4. Analytical column - Stainless steel, packed with small particles (usually ≤10 μm) of stationary phase
5. Detector - Identifies compounds as they elute:
   • UV/Vis detector (most common)
   • Fluorescence detector (sensitive, selective)
   • Mass spectrometer (HPLC-MS - gold standard)
   • Refractive index detector
   • Electrochemical detector
6. Data acquisition system - Records chromatogram (peak vs. time)

Types of HPLC

Applications in Pharmacology/Biochemical Assay

1. Drug analysis: Quantification of drugs and metabolites in plasma, urine, tissues (bioavailability, PK studies)
2. Quality control: Assay of active pharmaceutical ingredients (APIs) and impurities in formulations
3. Forensic analysis: Detection of heroin, LSD, amphetamines, cannabis in biological samples
4. Pharmaceutical: Stability testing, dissolution testing
5. Pesticide residue analysis: In blood, tissue, water
6. Protein/peptide analysis: Hormone assays, insulin quantification
7. Clinical diagnostics: HbA1c measurement using HPLC

Advantages

• High sensitivity and specificity
• Can detect thermally unstable compounds (unlike GC)
• Quantitative and qualitative analysis
• Automated, reproducible
• Wide range of analytes (small molecules to large proteins)

Disadvantages

• High capital cost
• Requires skilled personnel
• Mobile phase solvents can be toxic
• Column maintenance

---

Q5. (b) Limitations of Animal Testing [5 Marks]

Introduction

1. Species Differences (Inter-species Variability)

• Metabolic pathways, receptor pharmacology, and toxicological responses differ across species
• Examples:
  • Thalidomide was safe in rats but caused phocomelia in humans
  • Penicillin is toxic to guinea pigs but safe in humans
  • Aspirin is teratogenic in rats at doses safe in humans
• Drug metabolism enzymes (CYP isoforms) have different expression and activity profiles
• Body size, metabolic rate, lifespan all differ

2. Poor Predictive Value for Human Toxicity

• Studies show only 50-60% of animal toxicities predict human toxicities
• Many drugs that pass animal testing fail in human trials due to unexpected toxicity
• Conversely, some drugs are falsely abandoned due to animal toxicity not relevant to humans

3. Ethical and Moral Concerns

• Use of sentient creatures for experiments raises serious ethical issues
• Pain, distress, fear, suffering are experienced by animals
• Growing public pressure and animal rights advocacy

4. Cost and Time

• Long-term carcinogenicity studies (2 years) are very expensive (>$1-2 million per study)
• Time-consuming, delaying drug development
• Large number of animals required

5. Inability to Model Complex Human Conditions

• Cannot model psychological/social dimensions of human disease
• Many human conditions (schizophrenia, bipolar disorder) are poorly replicated in animals
• Lack of language/self-report means pain assessment is subjective

6. Genetic and Microbiome Differences

• Inbred strains may not represent genetic diversity of human patients
• Gut microbiome composition differs, affecting drug metabolism

7. Practical Limitations

• Housing, feeding, handling costs
• Limited by CPCSEA/IAEC approvals
• Need specialized trained personnel

8. Anesthetic and Handling Stress

• Stress of handling, restraint, injection can alter physiological parameters, confounding results

9. Regulatory-Driven Testing May Not Predict Real-World Use

• Standard test conditions (fixed doses, young healthy animals) do not reflect polypharmacy, elderly, diseased humans

Alternatives (3Rs)

• In vitro: Cell cultures, organoids, organ-on-a-chip
• In silico: QSAR models, pharmacokinetic modeling
• Human tissue models: Induced pluripotent stem cells (iPSCs)
• Microdosing studies in humans

---

Q6. (a) Discuss Langendorff Apparatus [5 Marks]

Introduction

Principle

Components of Langendorff Setup

1. Perfusion reservoir - Contains oxygenated Krebs-Henseleit buffer
2. Oxygenation system - 95% O2 + 5% CO2 gas mixture (carbogen)
3. Temperature control - Water jacket maintaining 37°C
4. Peristaltic pump or gravity feed - Delivers perfusate at constant pressure (70-80 mmHg) or flow rate
5. Aortic cannula - Connected to the isolated aorta
6. Pressure transducer - Measures perfusion pressure
7. Isometric/isotonic force transducer - Connected to apex of heart to measure contractile force
8. Data acquisition system - Records heart rate, contractile force, ECG

Perfusion Solution

• Krebs-Henseleit buffer (standard):
  • NaCl 118.5 mM, KCl 4.7 mM, CaCl2 2.5 mM, MgSO4 1.2 mM, NaHCO3 25 mM, KH2PO4 1.2 mM, Glucose 10 mM
  • pH 7.4, equilibrated with 95% O2/5% CO2

Modes of Langendorff Perfusion

Applications

1. Cardiac pharmacology: Testing effects of drugs on heart rate (chronotropy), force of contraction (inotropy), coronary flow
2. Ischemia-reperfusion injury: Global or regional ischemia models; studying cardioprotection
3. Arrhythmia studies: Induced by drugs (ouabain, aconitine); anti-arrhythmic drug testing
4. Coronary vasoactivity: Vasodilators/vasoconstrictors on coronary flow
5. Metabolic studies: Cardiac oxygen consumption, glucose/fatty acid utilization
6. Preconditioning studies: Ischemic or pharmacological preconditioning

Parameters Measured

• Heart rate (HR)
• Left ventricular developed pressure (LVDP)
• dP/dt max and min (rate of pressure change - index of contractility)
• Coronary flow rate
• ECG (rhythm)
• Oxygen consumption
• Enzyme release (LDH, CK - markers of damage)

Species Used

• Rat and mouse (most common, small isolated hearts)
• Guinea pig, rabbit (larger hearts)

Advantages

• Isolated system - no hormonal/neural influences
• Direct drug effects on heart studied
• Easy drug administration
• Reproducible, quantitative
• Reduces in vivo animal use

Disadvantages

• Not a whole-body preparation (no blood, no hormonal control)
• Perfusate is not blood (no red blood cells, plasma proteins)
• Limited viability (2-4 hours typically)
• Requires technical expertise
• Heart is not under physiological preload/afterload conditions

---

Q6. (b) Principle of PCR and Its Application [5 Marks]

Introduction

Principle

Step 1: Denaturation (>90-95°C)

• DNA double helix is heat-denatured (unwound) to produce two single-stranded template molecules
• Hydrogen bonds between base pairs are broken

Step 2: Annealing (50-75°C)

• Two short, synthetic oligonucleotide primers (typically 18-25 nucleotides) anneal to complementary sequences on opposite strands of the denatured DNA
• Primers flank the target sequence on either side
• Primer design determines specificity of amplification

Step 3: Extension (72°C)

• Taq DNA polymerase (heat-stable polymerase from thermophilic bacterium Thermus aquaticus) synthesizes new DNA strands starting from the 3' end of each primer
• All four dNTPs (dATP, dCTP, dGTP, dTTP) are incorporated
• Extension occurs in the 5'→3' direction
• Synthesis continues until the polymerase falls off or the cycle ends

• 20 cycles = ~10^6 (2^20) amplification
• 30 cycles = ~10^9 (2^30) amplification
• Each cycle takes 1-5 minutes; typical PCR run = 30 cycles in 1-3 hours

Components of a PCR Reaction

Variants of PCR

Applications of PCR

1. Medical Diagnostics

• Detection of infectious agents: HIV, HCV, HBV, TB (Mycobacterium tuberculosis), COVID-19 (RT-qPCR)
• Detection of latent viruses: HPV, CMV, EBV
• Rapid diagnosis when culture takes weeks

2. Genetic Disease Diagnosis

• Prenatal diagnosis: Sickle cell anemia, thalassemia, cystic fibrosis
• Carrier detection
• Newborn screening

3. Mutation Detection

• Cancer diagnostics: BRAF, EGFR, KRAS mutations
• Pharmacogenomics: CYP2D6, CYP2C19 genotyping (dosing adjustment)

4. Forensic Medicine

• DNA fingerprinting from minute samples (hair follicle, blood spot, spermatozoon)
• Paternity testing
• Crime scene analysis

5. Research Applications

• Cloning: Amplify gene of interest for insertion into vectors
• Gene expression studies (RT-qPCR)
• Site-directed mutagenesis
• Sequencing (PCR products used for Sanger sequencing, NGS)

6. Transplantation

• HLA typing for tissue matching

7. Environmental Microbiology

• Detection of pathogens in water/food

---

Summary Table - All Questions